PLEASE COMPLETE ACCURATELY AND FULLY. THIS INFORMATION IS NEEDED FOR AN ACCURATE AND TIMELY EVALUATION AND PROCESSING OF YOUR INVENTION.

Note: If multiple varieties/experimental lines have the same development period, include all in a single disclosure form.

1.

|  |  |  |
| --- | --- | --- |
| SPECIES: |  | |
| NAME OF VARIETY(S): |  | |
| EXPERIMENTAL DESIGNATION(S): |  | |
| PROPAGULE TYPE (clone, inbred, hybrid, population) |  | |
| Development Period1 | Beginning | End |
| 1The beginning of the development period is the fiscal year in which: 1) in the case of a pure line or clonally propagated line, the final cross was made leading to the population from which the variety was selected; 2) in the case of cross-pollinated synthetic varieties, the parents of the variety were selected from the source population; 3) in the case of backcross derived varieties, the initial cross was made; 4) in the case of inbred lines for hybrid varieties, the first selfing from the source of the inbred line was made; 5) in the case of microorganism-specific varieties, the variety was first altered with or using systemic microbes; or 6) in the case of mutagenesis and/or transformation of the parents of a variety, the mutant or primary transformant was detected in the parents of the variety.  The end of the development period is the first fiscal year in which: 1) the variety was advanced into federal registration trials, in the case of normal varieties or hybrids requiring registration; 2) an application was submitted for Plant Breeders' Rights or similar form of protection; 3) the experimental line or variety was released to a third party under a commercial licensing agreement; 4) propagation of the experimental line or variety was initiated for commercial purposes such as pedigreed seed increase; or 5) the variety was disclosed. | | |

2. INVENTORS: Give the names and positions of all individuals (faculty, research associates, post doctoral fellows, staff, students, etc.) who may have made an intellectual input into the invention. Those who simply followed instructions would not qualify as inventors. If there is any doubt include the name and mark with a "?".

|  |  |  |
| --- | --- | --- |
| Name | Position | Percent contribution (total=100) |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

3. PEDIGREE AND BREEDING METHODS

i) Describe the crosses and breeding methods used to develop the variety.

**If non-University of Guelph varieties/germplasm stocks were used as parents, please include copies of the Materials Transfer Agreements or similar documentation governing their use for breeding.**

ii) Do the varieties contain traits subject to license from a third-party?

|  |
| --- |
| Note: Information provided in the following five sections (4 through 8) may be publicly disclosed to external agencies as part of the tender and licensing process. Any information that should remain confidential should be listed in section 9.  This information could also be summarized in a spreadsheet. |

4. BRIEF DESCRIPTION

Give a short description of the invention indicating its attributes and region of adaptation and/or application.

5. PERFORMANCE

Where has the variety been tested? If available, provide a summary of performance relative to existing varieties.

6. UNIQUE CHARACTERISTICS

Does the variety have unique feature or a combination of features not found in varieties currently in the marketplace?

7. COMMERCIALIZATION STATUS

Has an application for Plant Breeders’ Rights, Plant Variety Protection, or Plant Patents been initiated or completed? If so, give dates, regions, and reference numbers for any that are in process or completed.

8. STATUS OF PEDIGREED STOCK

Describe the status of the maintenance and increase of pedigreed stock. Who will maintain the breeder stocks? What quantities are/will be available to initiate commercial distribution?

9. MARKET AND OTHER CONFIDENTIAL INFORMATION

i) Does any third-party have a license option to the variety under a research agreement?

ii) Has any third-party received the variety for evaluation? If yes, please list them.

iii) Has any market analysis been conducted? Has any external party indicated interest in the technology?

10. RESEARCH SUPPORT

**The technology has been developed through support of OMAFRA if at least 10% of the research funding and support has been provided from OMAFRA. I/we have elected to use a 1/3 OMAFRA 2/3 University ratio for allocation of cost/benefit associated with the varieties.**

*Note: If you do not wish to elect the 1/3, 2/3 ratio, you will have a maximum two months from the date of disclosure to document all sources of funding support provided by all sponsors including OMAFRA for the research which led to the invention. Use only support received during the development period. Identify the support received from each funding source in each fiscal year of the development period. Summarize this report in an Excel spreadsheet to compute the OMAFRA:University ratio of funding associated with the invention; round dollar figures to the nearest dollar, round percentages to two decimals. Also include the FRS project and trust account numbers for each source.*

FUNDING SUMMARY

|  |  |  |
| --- | --- | --- |
| Funding sources | Total | % |
| OMAFRA |  | 33.33 |
| University |  | 66.67 |
| Total |  | 100 |

11. SIGNATURES OF INVENTORS

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Inventor’s Signature |  | Date |
|  |  |  |
| Inventor’s Signature |  | Date |